Cytori Therapeutics recently announced that its Phase 3 STAR clinical trial, evaluating the efficacy and safety of Cytori Cell Therapy in scleroderma…
Margarida Azevedo, MSc
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Azevedo, MSc
A two-year study found that 80 percent of systemic sclerosis (SSc) patients had deficient levels of vitamin D when compared to healthy controls, and…
miRagen Therapeutics, Inc, a biopharmaceutical company working to develop microRNA-based therapeutic agents for a range of diseases, recently announced the initiation…
In a new research paper, scientists at the Faculty of Dentistry, Aristotle University of Thessaloniki, Greece, presented a clinical report…